Quince Therapeutics Publishes Positive Phase 3 Data on eDSP for Ataxia-Telangiectasia, Highlighting Sustained Drug Release and Favorable Safety Profile

Reuters09-26
Quince <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Publishes Positive Phase 3 Data on eDSP for Ataxia-Telangiectasia, Highlighting Sustained Drug Release and Favorable Safety Profile

Quince Therapeutics Inc. has announced the publication of a new population pharmacokinetic $(PK)$ modeling study of its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate encapsulated in a patient's own red blood cells), in the journal CPT: Pharmacometrics & Systems Pharmacology. The study focused on pediatric patients with Ataxia-Telangiectasia (A-T) and healthy adults, evaluating monthly administration of eDSP and predicting drug exposure in the A-T patient population over a six-month period. Results from the study indicate that eDSP maintains low, sustained plasma concentrations of DSP for 20 to 30 days without drug accumulation. Previous clinical trials, including the Phase 3 ATTeST trial and Open Label Extension study, reported a favorable safety profile for eDSP, with minimized corticosteroid-related side effects and no evidence of drug accumulation after repeated dosing. The results of this PK modeling study have already been published.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250925856162) on September 25, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment